SEC Form 4 · accession 0000899243-17-002381
Jounce Therapeutics, Inc. · JNCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Period of report
Feb 1, 2017
Accepted (ET)
Feb 1, 2017 · 6:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001640455
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 1, 2017 | C | 719,476 | — | A | 719,476 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Convertible Preferred StockF1 | — | Feb 1, 2017 | C | 2,654,867 | D | — | — | Common Stock | 719,476 | 0 | D |
Explanation of responses
- F1Each share of Series B convertible preferred stock converted into 0.271003 shares of common stock immediately prior to the amendment and restatement by Jounce Therapeutics, Inc. of its certificate of incorporation in connection with the closing of its initial public offering, and had no expiration date.